You are here

Mol Genet Genomic Med DOI:10.1002/mgg3.453

Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience.

Publication TypeJournal Article
Year of Publication2018
AuthorsPorter, KM, Kauffman, TL, Koenig, BA, Lewis, KL, Rehm, HL, Richards, CSue, Strande, NT, Tabor, HK, Wolf, SM, Yang, Y, Amendola, LM, Azzariti, DR, Berg, JS, Bergstrom, K, Biesecker, LG, Biswas, S, Bowling, KM, Chung, WK, Clayton, EW, Conlin, LK, Cooper, GM, Dulik, MC, Garraway, LA, Ghazani, AA, Green, RC, Hiatt, SM, Jamal, SM, Jarvik, GP, Goddard, KAB, Wilfond, BS
Corporate Authorsmembers of the CSER Actionability and Return of Results Working Group
JournalMol Genet Genomic Med
Date Published2018 Aug 21
ISSN2324-9269
Abstract

BACKGROUND: Clinical genome and exome sequencing (CGES) is primarily used to address specific clinical concerns by detecting risk of future disease, clarifying diagnosis, or directing treatment. Additionally, CGES makes possible the disclosure of autosomal recessive and X-linked carrier results as additional secondary findings, and research about the impact of carrier results disclosure in this context is needed.

METHODS: Representatives from 11 projects in the clinical sequencing exploratory research (CSER) consortium collected data from their projects using a structured survey. The survey focused on project characteristics, which variants were offered and/or disclosed to participants as carrier results, methods for carrier results disclosure, and project-specific outcomes. We recorded quantitative responses and report descriptive statistics with the aim of describing the variability in approaches to disclosing carrier results in translational genomics research projects.

RESULTS: The proportion of participants with carrier results was related to the number of genes included, ranging from 3% (three genes) to 92% (4,600 genes). Between one and seven results were disclosed to those participants who received any positive result. Most projects offered participants choices about whether to receive some or all of the carrier results. There were a range of approaches to communicate results, and many projects used separate approaches for disclosing positive and negative results.

CONCLUSION: Future translational genomics research projects will need to make decisions regarding whether and how to disclose carrier results. The CSER consortium experience identifies approaches that balance potential participant interest while limiting impact on project resources.

DOI10.1002/mgg3.453
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30133189?dopt=Abstract

Alternate JournalMol Genet Genomic Med
PubMed ID30133189